Contraceptive Technology Update – July 1, 2011
July 1, 2011
View Issues
-
Data emerges on drospirenone pills: How to counsel on their use
Results of two case-control studies indicate that women without risk factors for venous thromboembolism (VTE) who use oral contraceptives (OCs) containing drospirenone have an increased risk for nonfatal VTE compared with those who use levonorgestrel OCs. -
EC: Healthcare providers are not counseling
A just-published study indicates that many providers are failing to counsel women on the availability of emergency contraception (EC). -
New HPV test gains approval from FDA
Add another human papillomavirus (HPV) test to the clinical arsenal. The Food and Drug Administration (FDA) has approved the Roche cobas HPV Test. -
Is your radar up regarding herpes risk?
Results of a new study indicate patients who have tested positive for herpes simplex virus type 2 (HSV-2) but don't have symptoms or genital lesions still experience virus shedding during subclinical episodes. -
New approach eyed for recurrent UTIs
One woman in five develops a urinary tract infection (UTI) during her lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases. -
Washington Watch: Providers look to help from workforce program
For four decades, safety-net providers such as community health centers have turned to the National Health Service Corps (NHSC) for help with maintaining a well-trained and credentialed workforce. -
CT Updates: FDA issues warning on fraudulent STD drugs
The Food and Drug Administration (FDA) and the Federal Trade Commission have issued a joint call to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases (STDs). -
STI Quarterly: HIV prevention trial halted — What's the next step in clinical research?
Investigators have discontinued the FEM-PrEP study of oral emtricitabine and tenofovir disoproxil fumarate (Truvada, Gilead Sciences, Foster City, CA) to prevent HIV infection in women in Africa after interim results indicated the research would be unlikely to prove effectiveness in the study population. -
STI Quarterly: Heighten awareness to lower chlamydia numbers
What will it take to drive down the number of chlamydia infections in young women? While routine chlamydia screening is recommended for all sexually active females age 24 years and younger, only about half (49.9%) were screened during 2008-09, according to data collected in more than 1,000 U.S. health plans.